Shortness of breath, a 'wearing-off' symptom in Parkinson's disease.
Identifieur interne : 000D93 ( PubMed/Checkpoint ); précédent : 000D92; suivant : 000D94Shortness of breath, a 'wearing-off' symptom in Parkinson's disease.
Auteurs : Waqas Khan [Canada] ; Sughra Naz ; Abdul Qayyum RanaSource :
- Clinical drug investigation [ 1173-2563 ] ; 2009.
English descriptors
- KwdEn :
- Antiparkinson Agents (therapeutic use), Catechols (therapeutic use), Drug Resistance, Humans, Levodopa (therapeutic use), Male, Middle Aged, Nitriles (therapeutic use), Parkinson Disease (complications), Parkinson Disease (drug therapy), Respiratory Mechanics, Respiratory Tract Diseases (diagnosis), Respiratory Tract Diseases (etiology).
- MESH :
- chemical , therapeutic use : Antiparkinson Agents, Catechols, Levodopa, Nitriles.
- complications : Parkinson Disease.
- diagnosis : Respiratory Tract Diseases.
- drug therapy : Parkinson Disease.
- etiology : Respiratory Tract Diseases.
- Drug Resistance, Humans, Male, Middle Aged, Respiratory Mechanics.
Abstract
Although levodopa is considered the gold standard for Parkinson's disease therapy, prolonged use of this drug can result in motor complications such as a 'wearing-off' phenomenon. This outcome is seen in a significant number of patients with Parkinson's disease taking levodopa and, in some cases, is observed only a few hours after intake of the last dose of levodopa. Patients experiencing the wearing-off period may present with sensory, autonomic, psychiatric and motor fluctuations. Although infrequent, shortness of breath is an important non-motor wearing-off symptom experienced by patients with Parkinson's disease. In addition to being a symptom induced by wearing off, other causes of shortness of breath include pulmonary diseases, coronary artery disease and anxiety. Thus, it is important to identify the cause of shortness of breath to ensure that the appropriate treatment is initiated. We report here on a patient with Parkinson's disease who was taking levodopa and developed both shortness of breath and hyperventilation during wearing-off periods. He underwent extensive pulmonary and cardiac investigations that were unremarkable. His shortness of breath was determined to be a wearing-off phenomenon and his condition improved with the addition of a catechol-O-methyltransferase inhibitor (entacapone).
DOI: 10.2165/11315290-000000000-00000
PubMed: 19715385
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:19715385Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Shortness of breath, a 'wearing-off' symptom in Parkinson's disease.</title><author><name sortKey="Khan, Waqas" sort="Khan, Waqas" uniqKey="Khan W" first="Waqas" last="Khan">Waqas Khan</name><affiliation wicri:level="1"><nlm:affiliation>Parkinson Clinic of Eastern Toronto and Movement Disorders Center, Toronto, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Parkinson Clinic of Eastern Toronto and Movement Disorders Center, Toronto, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Naz, Sughra" sort="Naz, Sughra" uniqKey="Naz S" first="Sughra" last="Naz">Sughra Naz</name></author><author><name sortKey="Rana, Abdul Qayyum" sort="Rana, Abdul Qayyum" uniqKey="Rana A" first="Abdul Qayyum" last="Rana">Abdul Qayyum Rana</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2009">2009</date><idno type="RBID">pubmed:19715385</idno><idno type="pmid">19715385</idno><idno type="doi">10.2165/11315290-000000000-00000</idno><idno type="wicri:Area/PubMed/Corpus">000F10</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000F10</idno><idno type="wicri:Area/PubMed/Curation">000F10</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000F10</idno><idno type="wicri:Area/PubMed/Checkpoint">000F10</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000F10</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Shortness of breath, a 'wearing-off' symptom in Parkinson's disease.</title><author><name sortKey="Khan, Waqas" sort="Khan, Waqas" uniqKey="Khan W" first="Waqas" last="Khan">Waqas Khan</name><affiliation wicri:level="1"><nlm:affiliation>Parkinson Clinic of Eastern Toronto and Movement Disorders Center, Toronto, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Parkinson Clinic of Eastern Toronto and Movement Disorders Center, Toronto, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Naz, Sughra" sort="Naz, Sughra" uniqKey="Naz S" first="Sughra" last="Naz">Sughra Naz</name></author><author><name sortKey="Rana, Abdul Qayyum" sort="Rana, Abdul Qayyum" uniqKey="Rana A" first="Abdul Qayyum" last="Rana">Abdul Qayyum Rana</name></author></analytic><series><title level="j">Clinical drug investigation</title><idno type="ISSN">1173-2563</idno><imprint><date when="2009" type="published">2009</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiparkinson Agents (therapeutic use)</term><term>Catechols (therapeutic use)</term><term>Drug Resistance</term><term>Humans</term><term>Levodopa (therapeutic use)</term><term>Male</term><term>Middle Aged</term><term>Nitriles (therapeutic use)</term><term>Parkinson Disease (complications)</term><term>Parkinson Disease (drug therapy)</term><term>Respiratory Mechanics</term><term>Respiratory Tract Diseases (diagnosis)</term><term>Respiratory Tract Diseases (etiology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Catechols</term><term>Levodopa</term><term>Nitriles</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Respiratory Tract Diseases</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Respiratory Tract Diseases</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Drug Resistance</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Respiratory Mechanics</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Although levodopa is considered the gold standard for Parkinson's disease therapy, prolonged use of this drug can result in motor complications such as a 'wearing-off' phenomenon. This outcome is seen in a significant number of patients with Parkinson's disease taking levodopa and, in some cases, is observed only a few hours after intake of the last dose of levodopa. Patients experiencing the wearing-off period may present with sensory, autonomic, psychiatric and motor fluctuations. Although infrequent, shortness of breath is an important non-motor wearing-off symptom experienced by patients with Parkinson's disease. In addition to being a symptom induced by wearing off, other causes of shortness of breath include pulmonary diseases, coronary artery disease and anxiety. Thus, it is important to identify the cause of shortness of breath to ensure that the appropriate treatment is initiated. We report here on a patient with Parkinson's disease who was taking levodopa and developed both shortness of breath and hyperventilation during wearing-off periods. He underwent extensive pulmonary and cardiac investigations that were unremarkable. His shortness of breath was determined to be a wearing-off phenomenon and his condition improved with the addition of a catechol-O-methyltransferase inhibitor (entacapone).</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19715385</PMID><DateCreated><Year>2009</Year><Month>08</Month><Day>31</Day></DateCreated><DateCompleted><Year>2009</Year><Month>11</Month><Day>16</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1173-2563</ISSN><JournalIssue CitedMedium="Print"><Volume>29</Volume><Issue>10</Issue><PubDate><Year>2009</Year></PubDate></JournalIssue><Title>Clinical drug investigation</Title><ISOAbbreviation>Clin Drug Investig</ISOAbbreviation></Journal><ArticleTitle>Shortness of breath, a 'wearing-off' symptom in Parkinson's disease.</ArticleTitle><Pagination><MedlinePgn>689-91</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2165/11315290-000000000-00000</ELocationID><Abstract><AbstractText>Although levodopa is considered the gold standard for Parkinson's disease therapy, prolonged use of this drug can result in motor complications such as a 'wearing-off' phenomenon. This outcome is seen in a significant number of patients with Parkinson's disease taking levodopa and, in some cases, is observed only a few hours after intake of the last dose of levodopa. Patients experiencing the wearing-off period may present with sensory, autonomic, psychiatric and motor fluctuations. Although infrequent, shortness of breath is an important non-motor wearing-off symptom experienced by patients with Parkinson's disease. In addition to being a symptom induced by wearing off, other causes of shortness of breath include pulmonary diseases, coronary artery disease and anxiety. Thus, it is important to identify the cause of shortness of breath to ensure that the appropriate treatment is initiated. We report here on a patient with Parkinson's disease who was taking levodopa and developed both shortness of breath and hyperventilation during wearing-off periods. He underwent extensive pulmonary and cardiac investigations that were unremarkable. His shortness of breath was determined to be a wearing-off phenomenon and his condition improved with the addition of a catechol-O-methyltransferase inhibitor (entacapone).</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Khan</LastName><ForeName>Waqas</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Parkinson Clinic of Eastern Toronto and Movement Disorders Center, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Naz</LastName><ForeName>Sughra</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Rana</LastName><ForeName>Abdul Qayyum</ForeName><Initials>AQ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Clin Drug Investig</MedlineTA><NlmUniqueID>9504817</NlmUniqueID><ISSNLinking>1173-2563</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002396">Catechols</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009570">Nitriles</NameOfSubstance></Chemical><Chemical><RegistryNumber>46627O600J</RegistryNumber><NameOfSubstance UI="D007980">Levodopa</NameOfSubstance></Chemical><Chemical><RegistryNumber>4975G9NM6T</RegistryNumber><NameOfSubstance UI="C071192">entacapone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000978" MajorTopicYN="N">Antiparkinson Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002396" MajorTopicYN="N">Catechols</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004351" MajorTopicYN="N">Drug Resistance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007980" MajorTopicYN="N">Levodopa</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009570" MajorTopicYN="N">Nitriles</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015656" MajorTopicYN="N">Respiratory Mechanics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012140" MajorTopicYN="N">Respiratory Tract Diseases</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>9</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>9</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>11</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19715385</ArticleId><ArticleId IdType="pii">7</ArticleId><ArticleId IdType="doi">10.2165/11315290-000000000-00000</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Canada</li></country></list><tree><noCountry><name sortKey="Naz, Sughra" sort="Naz, Sughra" uniqKey="Naz S" first="Sughra" last="Naz">Sughra Naz</name><name sortKey="Rana, Abdul Qayyum" sort="Rana, Abdul Qayyum" uniqKey="Rana A" first="Abdul Qayyum" last="Rana">Abdul Qayyum Rana</name></noCountry><country name="Canada"><noRegion><name sortKey="Khan, Waqas" sort="Khan, Waqas" uniqKey="Khan W" first="Waqas" last="Khan">Waqas Khan</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000D93 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000D93 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:19715385
|texte= Shortness of breath, a 'wearing-off' symptom in Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:19715385" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonCanadaV1
| This area was generated with Dilib version V0.6.29. |  |